PacBio has released new software, which has increased read lengths and throughput, and aims to launch a new sample prep protocol and chemistry this year.
Although PacBio's product and services revenues were up 17 percent, total revenues declined 3 percent due to a lack of contractual revenue in the quarter.
The firms plan to focus on sample processing methods, workflow automation, algorithms, and database construction.
The firm is aiming to sell 15.4 million shares of common stock at $3.10 per share, and plans to use the proceeds for working capital and capital expenditures.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
The GenomeWeb Index rose nearly 6 percent in April, vastly outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million.
Oxford Nanopore filed two lawsuits, one in the UK and one in Germany.
In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.
Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.